---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-018362"
form_type: "8-K"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2026-02-23T23:59:59+00:00"
generated_at: "2026-05-16T01:14:36.480595+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# TransCode publishes preclinical RIG-I agonist data in Molecular Imaging and Biology

## Summary
- Manuscript published Feb 19, 2026 in Molecular Imaging and Biology.
- Novel template-driven RIG-I agonist activates innate immunity selectively in tumor cells.
- Uses overexpressed miRNA-21 as intracellular assembly template; aims to reduce systemic toxicity.
- Study conducted with Prof. Anna Moore (Michigan State Univ.) and TransCode CSO Zdravka Medarova.
- TTX nanoparticle delivery platform underpins the approach; currently in clinical trials.

## SEC filing metadata
- accession: 0001104659-26-018362
- form_type: 8-K
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2026-02-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465926018362/0001104659-26-018362-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465926018362/tm266952d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-018362
- JSON: https://secwatch.observer/filing/0001104659-26-018362.json
- Plain text: https://secwatch.observer/filing/0001104659-26-018362.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.